Malignant uterine smooth muscle tumors: Role of etoposide, cisplatin, and doxorubicin (EPA) chemotherapy

E. Resnik, Setsuko K Chambers, M. L. Carcangiu, E. I. Kohorn, P. E. Schwartz, J. T. Chambers

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Nearly 80% of patients with malignant uterine smooth muscle tumor will suffer local relapse and/or distant metastases after initial surgical resection. There is no convincing evidence that the addition of pelvic radiation improves the outcome. However, adjuvant chemotherapy might be an appropriate therapeutic modality. Methods: Between 1986 and 1991, 13 consecutive patients with malignant uterine smooth muscle tumors were treated at Yale-New Haven Hospital with a combination chemotherapy containing etoposide 100 mg/M2 on days 1 and 2, cisplatin 50 mg/M2 on day 1, and doxorubicin 50 mg/M2 on day 1, repeated every 28 days. Six patients had Stage I disease, one patient had Stage III disease, and six patients had Stage IV disease. The number of cycles ranged from 2 to 9. Results: The median follow-up was 30 months (range 4-81). The mean overall survival for the group was 43.1 ± 6.7 months, with the progression-free interval of 25.5 ± 8.0 months. Of the seven patients with evaluable disease, one patient had complete response and one had partial response (total response rate of 28.6%). Of the six patients treated adjuvantly, three recurred at 9, 33, and 59 months (recurrence rate of 50%). Conclusions: We conclude that this combination has only modest activity against malignant uterine smooth muscle tumors at the schedule and doses tested.

Original languageEnglish (US)
Pages (from-to)145-147
Number of pages3
JournalJournal of Surgical Oncology
Volume63
Issue number3
DOIs
StatePublished - Nov 1996
Externally publishedYes

Fingerprint

Smooth Muscle Tumor
Myometrium
Etoposide
Doxorubicin
Cisplatin
Drug Therapy
Recurrence
Adjuvant Chemotherapy
Combination Drug Therapy
Appointments and Schedules
Radiation
Neoplasm Metastasis
Survival

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Malignant uterine smooth muscle tumors : Role of etoposide, cisplatin, and doxorubicin (EPA) chemotherapy. / Resnik, E.; Chambers, Setsuko K; Carcangiu, M. L.; Kohorn, E. I.; Schwartz, P. E.; Chambers, J. T.

In: Journal of Surgical Oncology, Vol. 63, No. 3, 11.1996, p. 145-147.

Research output: Contribution to journalArticle

Resnik, E. ; Chambers, Setsuko K ; Carcangiu, M. L. ; Kohorn, E. I. ; Schwartz, P. E. ; Chambers, J. T. / Malignant uterine smooth muscle tumors : Role of etoposide, cisplatin, and doxorubicin (EPA) chemotherapy. In: Journal of Surgical Oncology. 1996 ; Vol. 63, No. 3. pp. 145-147.
@article{0c92c08bcad542b59fd9e081ac09844d,
title = "Malignant uterine smooth muscle tumors: Role of etoposide, cisplatin, and doxorubicin (EPA) chemotherapy",
abstract = "Background: Nearly 80{\%} of patients with malignant uterine smooth muscle tumor will suffer local relapse and/or distant metastases after initial surgical resection. There is no convincing evidence that the addition of pelvic radiation improves the outcome. However, adjuvant chemotherapy might be an appropriate therapeutic modality. Methods: Between 1986 and 1991, 13 consecutive patients with malignant uterine smooth muscle tumors were treated at Yale-New Haven Hospital with a combination chemotherapy containing etoposide 100 mg/M2 on days 1 and 2, cisplatin 50 mg/M2 on day 1, and doxorubicin 50 mg/M2 on day 1, repeated every 28 days. Six patients had Stage I disease, one patient had Stage III disease, and six patients had Stage IV disease. The number of cycles ranged from 2 to 9. Results: The median follow-up was 30 months (range 4-81). The mean overall survival for the group was 43.1 ± 6.7 months, with the progression-free interval of 25.5 ± 8.0 months. Of the seven patients with evaluable disease, one patient had complete response and one had partial response (total response rate of 28.6{\%}). Of the six patients treated adjuvantly, three recurred at 9, 33, and 59 months (recurrence rate of 50{\%}). Conclusions: We conclude that this combination has only modest activity against malignant uterine smooth muscle tumors at the schedule and doses tested.",
author = "E. Resnik and Chambers, {Setsuko K} and Carcangiu, {M. L.} and Kohorn, {E. I.} and Schwartz, {P. E.} and Chambers, {J. T.}",
year = "1996",
month = "11",
doi = "10.1002/(SICI)1096-9098(199611)63:3<145::AID-JSO3>3.0.CO;2-D",
language = "English (US)",
volume = "63",
pages = "145--147",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Malignant uterine smooth muscle tumors

T2 - Role of etoposide, cisplatin, and doxorubicin (EPA) chemotherapy

AU - Resnik, E.

AU - Chambers, Setsuko K

AU - Carcangiu, M. L.

AU - Kohorn, E. I.

AU - Schwartz, P. E.

AU - Chambers, J. T.

PY - 1996/11

Y1 - 1996/11

N2 - Background: Nearly 80% of patients with malignant uterine smooth muscle tumor will suffer local relapse and/or distant metastases after initial surgical resection. There is no convincing evidence that the addition of pelvic radiation improves the outcome. However, adjuvant chemotherapy might be an appropriate therapeutic modality. Methods: Between 1986 and 1991, 13 consecutive patients with malignant uterine smooth muscle tumors were treated at Yale-New Haven Hospital with a combination chemotherapy containing etoposide 100 mg/M2 on days 1 and 2, cisplatin 50 mg/M2 on day 1, and doxorubicin 50 mg/M2 on day 1, repeated every 28 days. Six patients had Stage I disease, one patient had Stage III disease, and six patients had Stage IV disease. The number of cycles ranged from 2 to 9. Results: The median follow-up was 30 months (range 4-81). The mean overall survival for the group was 43.1 ± 6.7 months, with the progression-free interval of 25.5 ± 8.0 months. Of the seven patients with evaluable disease, one patient had complete response and one had partial response (total response rate of 28.6%). Of the six patients treated adjuvantly, three recurred at 9, 33, and 59 months (recurrence rate of 50%). Conclusions: We conclude that this combination has only modest activity against malignant uterine smooth muscle tumors at the schedule and doses tested.

AB - Background: Nearly 80% of patients with malignant uterine smooth muscle tumor will suffer local relapse and/or distant metastases after initial surgical resection. There is no convincing evidence that the addition of pelvic radiation improves the outcome. However, adjuvant chemotherapy might be an appropriate therapeutic modality. Methods: Between 1986 and 1991, 13 consecutive patients with malignant uterine smooth muscle tumors were treated at Yale-New Haven Hospital with a combination chemotherapy containing etoposide 100 mg/M2 on days 1 and 2, cisplatin 50 mg/M2 on day 1, and doxorubicin 50 mg/M2 on day 1, repeated every 28 days. Six patients had Stage I disease, one patient had Stage III disease, and six patients had Stage IV disease. The number of cycles ranged from 2 to 9. Results: The median follow-up was 30 months (range 4-81). The mean overall survival for the group was 43.1 ± 6.7 months, with the progression-free interval of 25.5 ± 8.0 months. Of the seven patients with evaluable disease, one patient had complete response and one had partial response (total response rate of 28.6%). Of the six patients treated adjuvantly, three recurred at 9, 33, and 59 months (recurrence rate of 50%). Conclusions: We conclude that this combination has only modest activity against malignant uterine smooth muscle tumors at the schedule and doses tested.

UR - http://www.scopus.com/inward/record.url?scp=0029826985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029826985&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-9098(199611)63:3<145::AID-JSO3>3.0.CO;2-D

DO - 10.1002/(SICI)1096-9098(199611)63:3<145::AID-JSO3>3.0.CO;2-D

M3 - Article

C2 - 8944057

AN - SCOPUS:0029826985

VL - 63

SP - 145

EP - 147

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -